Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system mistakenly destroys insulin-producing beta cells in the pancreas. For decades, treatment has focused on insulin replacement therapy—a life-saving but non-curative approach. The advent of next-generation sequencing (NGS) is now reshaping this landscape. By providing a high-resolution view of the human genome, NGS enables researchers and clinicians to identify the precise genetic drivers of T1D, paving the way for personalized cure strategies that target the root cause of the disease rather than just its symptoms.

This article explores how NGS is being applied across the entire T1D research and clinical spectrum—from genetic risk prediction and immune profiling to the development of tailored immunotherapies and regenerative treatments. The goal is a future in which each patient receives a treatment plan uniquely adapted to their genetic profile, improving outcomes, reducing side effects, and ultimately offering the possibility of a cure.

What Is Next-Generation Sequencing?

Next-generation sequencing refers to a suite of high-throughput DNA sequencing technologies that can read millions of DNA fragments in parallel. Unlike the older Sanger sequencing method, which sequences one fragment at a time, NGS can sequence an entire human genome in a single day at a fraction of the cost. Platforms such as Illumina (HiSeq, NovaSeq), Thermo Fisher (Ion Torrent), and Pacific Biosciences (PacBio) each offer unique strengths in read length, accuracy, and throughput, making NGS suitable for a wide range of applications.

In the context of T1D, NGS is used for whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted gene panels, RNA sequencing (transcriptomics), and epigenetic profiling. This comprehensive view allows researchers to detect single nucleotide variants, insertions, deletions, copy number variations, and structural rearrangements that may contribute to disease risk or progression.

The Role of NGS in Unraveling T1D Genetics

T1D has a strong genetic component: the risk of developing the disease is about 15 times higher in siblings of affected individuals than in the general population. Prior to NGS, genome-wide association studies (GWAS) identified more than 50 genetic loci associated with T1D, but these studies typically only captured common variants and could not explain the full heritability. NGS now fills that gap by detecting rare and low-frequency variants that GWAS often miss.

Identifying Risk Variants in the HLA Region

The human leukocyte antigen (HLA) region on chromosome 6 accounts for approximately 40–50% of the genetic risk for T1D. NGS enables high-resolution typing of classic HLA genes (e.g., HLA-DRB1, HLA-DQB1, HLA-DQA1) and also identifies non-classical HLA genes and regulatory elements that modulate immune responses. For example, specific amino acid differences at position 57 of the HLA-DQβ chain are strongly associated with T1D susceptibility, and NGS can pinpoint these details with precision.

Non-HLA Genes and Rare Variants

Beyond the HLA region, NGS has uncovered rare variants in genes such as INS (insulin gene), PTPN22, CTLA4, IL2RA, and SH2B3 that contribute to T1D risk. A 2020 study using whole-exome sequencing in families with multiple T1D cases identified novel rare variants in IFIH1 and CLEC16A that disrupt immune tolerance pathways (PubMed). Such findings are critical for understanding the heterogeneity of T1D and for stratifying patients into distinct genetic subgroups.

Epigenetics and Gene Regulation

NGS-based methods like chromatin immunoprecipitation sequencing (ChIP-seq) and whole-genome bisulfite sequencing (WGBS) reveal how environmental factors—such as viral infections, diet, and gut microbiome composition—can influence gene expression through DNA methylation and histone modifications. In T1D, altered methylation patterns in immune-related genes have been observed years before clinical diagnosis, suggesting that epigenetic marks could serve as early biomarkers (see Diabetes, 2021).

Metagenomics and the Gut Microbiome

NGS also enables shotgun metagenomic sequencing of the gut microbiome. Studies have found that children who develop T1D have a less diverse gut microbiome and a higher abundance of pro-inflammatory bacteria. By tracking microbiome changes over time using NGS, researchers hope to identify microbial triggers that could be targeted with probiotics or other interventions to prevent or delay T1D onset.

From Genetic Insights to Personalized Cure Strategies

The ultimate translational goal of NGS is to move from a one-size-fits-all approach to a personalized medicine paradigm for T1D. This involves using genetic information to predict risk, guide prevention, tailor immunotherapy, monitor disease progression, and even repair or replace beta cells.

Risk Prediction and Early Screening

Polygenic risk scores (PRS) derived from NGS data can now quantify an individual’s genetic predisposition to T1D with high accuracy. Large-scale initiatives like the Environmental Determinants of Diabetes in the Young (TEDDY) study use NGS to genotype newborns and follow them longitudinally. Combining PRS with autoantibody screening allows clinicians to identify children at imminent risk of developing T1D, enabling early interventions such as oral insulin trials or immune-modulating therapies. The Fr1da study in Germany has already demonstrated the feasibility of population-based screening using NGS-based HLA typing and autoantibody testing (The Lancet Diabetes & Endocrinology, 2020).

Tailored Immunotherapies

Perhaps the most direct application of NGS in personalized T1D cure strategies is in the selection and monitoring of immunotherapies. The FDA-approved drug teplizumab (a monoclonal antibody that targets CD3 on T cells) was shown to delay the onset of clinical T1D by a median of two years in high-risk individuals. However, not all patients respond equally. NGS can identify genetic markers of response—such as specific HLA alleles or variants in IL6R or PD-1—that predict whether a patient will benefit from teplizumab, abatacept, or other immune checkpoint modulators.

In practice, clinicians could genotype a patient at diagnosis and choose an immunotherapy with the highest predicted efficacy for that individual’s genetic subtype. For example, patients carrying a particular PTPN22 variant might be more responsive to therapies that boost regulatory T-cell function, whereas those with CTLA4 variants might benefit from CTLA-4 Ig fusion proteins like abatacept.

Monitoring Disease Progression with Liquid Biopsy

NGS-based liquid biopsies—analyzing cell-free DNA (cfDNA) in the blood—offer a non-invasive window into the health of the pancreas. In T1D, dying beta cells release methylated DNA fragments that can be detected and quantified by NGS (e.g., measurement of beta-cell-derived unmethylated insulin gene INS DNA). A 2022 study showed that the ratio of unmethylated to methylated INS DNA in plasma correlates with residual beta-cell mass and can predict impending loss of C-peptide production (Diabetes, 2022). This kind of dynamic monitoring allows physicians to adjust therapies in real time, potentially preserving remaining beta-cell function.

In addition, NGS-based immune repertoire sequencing (T-cell receptor and B-cell receptor sequencing) can track the expansion of autoreactive clones. Changes in clonal abundance may serve as a biomarker for disease activity and treatment response, enabling a more precise, data-driven approach to immunotherapy dosing and duration.

Beta-Cell Preservation and Regeneration

For patients who have already lost significant beta-cell mass, regenerative strategies offer hope. NGS is essential here in two ways. First, it can guide the generation of stem-cell-derived beta cells (SC-beta cells) by confirming that the cells carry the correct genetic background and lack potentially immunogenic variants. For autologous transplants, the patient’s own induced pluripotent stem cells (iPSCs) must be corrected of any T1D-associated risk alleles using gene editing tools like CRISPR-Cas9. NGS validates the edits and ensures no unintended off-target mutations.

Second, NGS helps identify patients who are suitable candidates for beta-cell regeneration trials. Some individuals retain a small population of alpha cells that can transdifferentiate into beta cells under the right conditions. Genetic signatures associated with alpha-to-beta cell plasticity—such as expression of ARX and PDX1—can be assessed using single-cell RNA sequencing, a specialized NGS method. Patients with a favorable epigenetic milieu might be enrolled in trials testing combination therapies of GLP-1 agonists, DYRK1A inhibitors, and immune modulation.

Challenges and Future Directions

Despite its enormous potential, the integration of NGS into routine T1D care faces several hurdles. Cost, while decreasing, is still substantial for whole-genome sequencing. Data interpretation requires sophisticated bioinformatics pipelines and a deep understanding of genetic variant classification. Many rare variants are of unknown significance (VUS), and functional studies are needed to determine their relevance. The ethical implications of genetic testing—particularly in children—must be carefully managed, including issues of privacy, genetic discrimination, and psychological impact.

Another challenge is the need for large, diverse cohorts to ensure that genomic findings are broadly applicable. Most T1D genetic studies to date have been conducted in populations of European descent, limiting the utility of PRS and variant interpretation in other ethnic groups. Initiatives like the Accelerating Medicines Partnership (AMP) T1D aim to address this by sequencing multi-ethnic cohorts and sharing data openly.

Looking ahead, the combination of NGS with other “omics” technologies—proteomics, metabolomics, and lipidomics—will provide a multi-layered picture of T1D pathogenesis. Artificial intelligence and machine learning algorithms will be crucial for integrating these datasets and predicting individualized disease trajectories and treatment responses. Already, researchers have developed deep learning models that use NGS-derived HLA sequences to predict T1D risk with area under the curve (AUC) values exceeding 0.90 (Scientific Reports, 2021).

Finally, as NGS technology becomes more portable—for example, nanopore sequencing devices that fit in a pocket—point-of-care genomic testing could become a reality. A newborn could be genotyped in the delivery room, and if high-risk T1D alleles are detected, an early monitoring and prevention program could begin immediately. Together with advances in gene therapy, islet encapsulation, and immune tolerance induction, NGS is a foundational tool in the quest for a personalized cure for T1D.

In summary, next-generation sequencing is not merely a research instrument—it is becoming an integral part of the clinical armamentarium against Type 1 Diabetes. From identifying genetic susceptibilities and monitoring autoimmune activity to guiding immunotherapy selection and enabling regenerative medicine, NGS provides the granularity needed to move beyond generic treatment protocols. The path to a cure for T1D is paved with genomic data, and NGS is the engine driving that transformation.